163 related articles for article (PubMed ID: 38585865)
1. Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes Without Known Heart Failure.
Wang D; Naumova A; Isquith D; Sapp J; Huynh KA; Tucker I; Balu N; Voronyuk A; Chu B; Ordovas K; Maynard C; Tian R; Zhao XQ; Kim F
Res Sq; 2024 Mar; ():. PubMed ID: 38585865
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure.
Wang DD; Naumova AV; Isquith D; Sapp J; Huynh KA; Tucker I; Balu N; Voronyuk A; Chu B; Ordovas K; Maynard C; Tian R; Zhao XQ; Kim F
Cardiovasc Diabetol; 2024 Jun; 23(1):197. PubMed ID: 38849829
[TBL] [Abstract][Full Text] [Related]
3. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
5. Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
Ortega-Paz L; Cristóbal H; Ortiz-Perez JT; García de Frutos P; Mendieta G; Sandoval E; Rodriguez JJ; Ortega E; García-Álvarez A; Brugaletta S; Sabaté M; Dantas AP
ESC Heart Fail; 2023 Feb; 10(1):453-464. PubMed ID: 36303443
[TBL] [Abstract][Full Text] [Related]
6. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
[TBL] [Abstract][Full Text] [Related]
7. Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study.
Oldgren J; Laurila S; Åkerblom A; Latva-Rasku A; Rebelos E; Isackson H; Saarenhovi M; Eriksson O; Heurling K; Johansson E; Wilderäng U; Karlsson C; Esterline R; Ferrannini E; Oscarsson J; Nuutila P
Diabetes Obes Metab; 2021 Jul; 23(7):1505-1517. PubMed ID: 33625777
[TBL] [Abstract][Full Text] [Related]
8. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
[TBL] [Abstract][Full Text] [Related]
9. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
Borlaug BA; Reddy YNV; Braun A; Sorimachi H; Omar M; Popovic D; Alogna A; Jensen MD; Carter R
Circulation; 2023 Sep; 148(10):834-844. PubMed ID: 37534453
[TBL] [Abstract][Full Text] [Related]
10. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
Leccisotti L; Cinti F; Sorice GP; D'Amario D; Lorusso M; Guzzardi MA; Mezza T; Gugliandolo S; Cocchi C; Capece U; Indovina L; Ferraro PM; Iozzo P; Crea F; Giordano A; Giaccari A
Cardiovasc Diabetol; 2022 Sep; 21(1):173. PubMed ID: 36057768
[TBL] [Abstract][Full Text] [Related]
13.
Yoshihara F; Imazu M; Sakuma I; Hiroi Y; Hara H; Okazaki O; Ishiguro C; Izumi C; Noguchi T; Shiraiwa T; Nishioka N; Fujii K; Iwakura K; Tomonaga O; Kobayashi K; Takihata M; Yumoto K; Takase H; Himi T; Shimizu I; Murakami T; Wagatsuma K; Sato K; Hiramatsu T; Akabame S; Hata S; Asakura M; Kawabata T; Omae K; Ito S; Kitakaze M;
EClinicalMedicine; 2023 Dec; 66():102334. PubMed ID: 38192595
[TBL] [Abstract][Full Text] [Related]
14. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
16. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
17. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial.
Veelen A; Andriessen C; Op den Kamp Y; Erazo-Tapia E; de Ligt M; Mevenkamp J; Jörgensen JA; Moonen-Kornips E; Schaart G; Esterline R; Havekes B; Oscarsson J; Schrauwen-Hinderling VB; Phielix E; Schrauwen P
Metabolism; 2023 Mar; 140():155396. PubMed ID: 36592688
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
van Ruiten CC; Smits MM; Kok MD; Serné EH; van Raalte DH; Kramer MHH; Nieuwdorp M; IJzerman RG
Cardiovasc Diabetol; 2022 Apr; 21(1):63. PubMed ID: 35484607
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
